MorphoSys AG

XTRA:MOR Stock Report

Market Cap: €2.5b

This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

MorphoSys Future Growth

Future criteria checks 2/6

MorphoSys is forecast to grow earnings and revenue by 59.1% and 25% per annum respectively. EPS is expected to grow by 78.2% per annum. Return on equity is forecast to be 7.7% in 3 years.

Key information

59.1%

Earnings growth rate

78.18%

EPS growth rate

Biotechs earnings growth20.6%
Revenue growth rate25.0%
Future return on equity7.68%
Analyst coverage

Good

Last updated05 Aug 2024

Recent future growth updates

Recent updates

Analysis Article • Apr 30

Would MorphoSys (ETR:MOR) Be Better Off With Less Debt?

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...
Analysis Article • Dec 25

MorphoSys AG's (ETR:MOR) 93% Share Price Surge Not Quite Adding Up

MorphoSys AG ( ETR:MOR ) shareholders would be excited to see that the share price has had a great month, posting a 93...
Analysis Article • Aug 24

Is MorphoSys (ETR:MOR) Weighed On By Its Debt Load?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Analysis Article • May 16

Does MorphoSys (ETR:MOR) Have A Healthy Balance Sheet?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Analysis Article • Apr 17

MorphoSys AG (ETR:MOR) Held Back By Insufficient Growth Even After Shares Climb 36%

MorphoSys AG ( ETR:MOR ) shareholders would be excited to see that the share price has had a great month, posting a 36...
Analysis Article • Nov 26

MorphoSys AG (ETR:MOR) Analysts Are More Bearish Than They Used To Be

Market forces rained on the parade of MorphoSys AG ( ETR:MOR ) shareholders today, when the analysts downgraded their...

Earnings and Revenue Growth Forecasts

XTRA:MOR - Analysts future estimates and past financials data (EUR Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2026425-78-120-505
12/31/2025322-140-236-2018
12/31/2024180-249-296-2533
3/31/2024241-469-286-284N/A
12/31/2023238-190-299-296N/A
9/30/2023223104-363-355N/A
6/30/2023255100-349-338N/A
3/31/2023261-61-321-306N/A
12/31/2022278-151-382-367N/A
9/30/2022250-861-436-417N/A
6/30/2022195-851-606-588N/A
3/31/2022174-596-610-583N/A
12/31/2021180-514-508-481N/A
9/30/2021163-150-423-393N/A
6/30/2021143-103-295-246N/A
3/31/2021124-177-255-217N/A
12/31/202032898-1435N/A
9/30/2020303642663N/A
6/30/202029310598113N/A
3/31/2020309153137152N/A
12/31/201972-103-85-81N/A
9/30/201971-96-68-64N/A
6/30/2019114-42-42-39N/A
3/31/201987-59-33-31N/A
12/31/201876-56-35-33N/A
9/30/201894-27-16-14N/A
6/30/201854-82-61-48N/A
3/31/201858-74-68-55N/A
12/31/201767-70N/A-38N/A
9/30/201752-84N/A-52N/A
6/30/201749-73N/A-59N/A
3/31/201749-68N/A-47N/A
12/31/201650-60N/A-47N/A
9/30/201649-45N/A-48N/A
6/30/201648-40N/A-41N/A
3/31/201648-33N/A-35N/A
12/31/201510615N/A-24N/A
9/30/201511127N/A-15N/A
6/30/201511633N/A-3N/A
3/31/201511937N/A-4N/A
12/31/201464-3N/A-14N/A
9/30/201461-6N/A-15N/A
6/30/201460-5N/A79N/A
3/31/2014777N/A76N/A
12/31/2013787N/A89N/A
9/30/20138014N/A100N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: MOR is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: MOR is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: MOR is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: MOR's revenue (25% per year) is forecast to grow faster than the German market (5.2% per year).

High Growth Revenue: MOR's revenue (25% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: MOR's Return on Equity is forecast to be low in 3 years time (7.7%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/08/05 23:30
End of Day Share Price 2024/08/05 00:00
Earnings2024/03/31
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

MorphoSys AG is covered by 20 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Olav ZilianBaader Helvea Equity Research
Brian BalchinBarclays
Rosie TurnerBarclays